drugset / Trial / NCT01817751
Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma
Phase 2
Completed
47 enrolled
Virginia Commonwealth University
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to test the safety, tolerability, and effectiveness of the combination of three drugs, sorafenib (Nexavar®), valproic acid (Depakote®), and sildenafil (Viagra®), when used to treat high-grade glioma, a type of brain tumor.
Timeline
- Start
- 2013-04-11
- Primary completion
- 2020-08-27
- Completion
- 2023-05-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sildenafil | Unknown | 50 mg | Oral |
| Subject | Sorafenib | Small molecule | 400 mg | Oral |
| Subject | Valproic Acid | Small molecule | — | Oral |